Logo image of PRTA

PROTHENA CORP PLC (PRTA) Stock Fundamental Analysis

NASDAQ:PRTA - Nasdaq - IE00B91XRN20 - Common Stock - Currency: USD

6.58  +0.03 (+0.46%)

After market: 5.01 -1.57 (-23.86%)

Fundamental Rating

4

PRTA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 562 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PRTA as it has an excellent financial health rating, but there are worries on the profitability. PRTA shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PRTA has reported negative net income.
In the past year PRTA has reported a negative cash flow from operations.
In the past 5 years PRTA reported 4 times negative net income.
PRTA had negative operating cash flow in 4 of the past 5 years.
PRTA Yearly Net Income VS EBIT VS OCF VS FCFPRTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M -150M

1.2 Ratios

PRTA has a better Return On Assets (-22.26%) than 76.29% of its industry peers.
PRTA has a better Return On Equity (-25.19%) than 82.17% of its industry peers.
Industry RankSector Rank
ROA -22.26%
ROE -25.19%
ROIC N/A
ROA(3y)-19.63%
ROA(5y)-16.25%
ROE(3y)-23.37%
ROE(5y)-23.22%
ROIC(3y)N/A
ROIC(5y)N/A
PRTA Yearly ROA, ROE, ROICPRTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

PRTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRTA Yearly Profit, Operating, Gross MarginsPRTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

7

2. Health

2.1 Basic Checks

PRTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRTA has more shares outstanding
The number of shares outstanding for PRTA has been increased compared to 5 years ago.
PRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PRTA Yearly Shares OutstandingPRTA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PRTA Yearly Total Debt VS Total AssetsPRTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of 0.68, we must say that PRTA is in the distress zone and has some risk of bankruptcy.
PRTA's Altman-Z score of 0.68 is fine compared to the rest of the industry. PRTA outperforms 68.09% of its industry peers.
There is no outstanding debt for PRTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.68
ROIC/WACCN/A
WACC7.69%
PRTA Yearly LT Debt VS Equity VS FCFPRTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 9.00 indicates that PRTA has no problem at all paying its short term obligations.
With a decent Current ratio value of 9.00, PRTA is doing good in the industry, outperforming 75.76% of the companies in the same industry.
PRTA has a Quick Ratio of 9.00. This indicates that PRTA is financially healthy and has no problem in meeting its short term obligations.
PRTA has a Quick ratio of 9.00. This is in the better half of the industry: PRTA outperforms 75.76% of its industry peers.
Industry RankSector Rank
Current Ratio 9
Quick Ratio 9
PRTA Yearly Current Assets VS Current LiabilitesPRTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.00% over the past year.
Looking at the last year, PRTA shows a very strong growth in Revenue. The Revenue has grown by 54.52%.
Measured over the past years, PRTA shows a very strong growth in Revenue. The Revenue has been growing by 178.96% on average per year.
EPS 1Y (TTM)36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.42%
Revenue 1Y (TTM)54.52%
Revenue growth 3Y-12.33%
Revenue growth 5Y178.96%
Sales Q2Q%5556%

3.2 Future

The Earnings Per Share is expected to grow by 29.44% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 43.11% on average over the next years. This is a very strong growth
EPS Next Y-60.6%
EPS Next 2Y-27%
EPS Next 3Y-10.55%
EPS Next 5Y29.44%
Revenue Next Year-63.67%
Revenue Next 2Y-10.08%
Revenue Next 3Y11.92%
Revenue Next 5Y43.11%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PRTA Yearly Revenue VS EstimatesPRTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
PRTA Yearly EPS VS EstimatesPRTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20 30 40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRTA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRTA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRTA Price Earnings VS Forward Price EarningsPRTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRTA Per share dataPRTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

PRTA's earnings are expected to decrease with -10.55% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27%
EPS Next 3Y-10.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PRTA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROTHENA CORP PLC

NASDAQ:PRTA (5/23/2025, 8:47:48 PM)

After market: 5.01 -1.57 (-23.86%)

6.58

+0.03 (+0.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners102.14%
Inst Owner Change-2.04%
Ins Owners16.17%
Ins Owner Change0%
Market Cap354.20M
Analysts81.25
Price Target52.79 (702.28%)
Short Float %17.1%
Short Ratio8.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.21%
Min EPS beat(2)-12.81%
Max EPS beat(2)-1.61%
EPS beat(4)2
Avg EPS beat(4)51.88%
Min EPS beat(4)-12.81%
Max EPS beat(4)213.55%
EPS beat(8)3
Avg EPS beat(8)51.37%
EPS beat(12)5
Avg EPS beat(12)33.26%
EPS beat(16)5
Avg EPS beat(16)19.71%
Revenue beat(2)0
Avg Revenue beat(2)-68.96%
Min Revenue beat(2)-72.37%
Max Revenue beat(2)-65.56%
Revenue beat(4)1
Avg Revenue beat(4)236.51%
Min Revenue beat(4)-72.37%
Max Revenue beat(4)1106.38%
Revenue beat(8)2
Avg Revenue beat(8)106.17%
Revenue beat(12)3
Avg Revenue beat(12)55.02%
Revenue beat(16)3
Avg Revenue beat(16)29.13%
PT rev (1m)0%
PT rev (3m)19.16%
EPS NQ rev (1m)-4.53%
EPS NQ rev (3m)-9.57%
EPS NY rev (1m)-0.21%
EPS NY rev (3m)12.15%
Revenue NQ rev (1m)-21.81%
Revenue NQ rev (3m)-54.06%
Revenue NY rev (1m)1.88%
Revenue NY rev (3m)-20.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.57
P/FCF N/A
P/OCF N/A
P/B 0.81
P/tB 0.81
EV/EBITDA N/A
EPS(TTM)-2.08
EYN/A
EPS(NY)-3.71
Fwd EYN/A
FCF(TTM)-2.43
FCFYN/A
OCF(TTM)-2.42
OCFYN/A
SpS2.56
BVpS8.13
TBVpS8.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.26%
ROE -25.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-19.63%
ROA(5y)-16.25%
ROE(3y)-23.37%
ROE(5y)-23.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.3%
Cap/Sales 0.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9
Quick Ratio 9
Altman-Z 0.68
F-Score4
WACC7.69%
ROIC/WACCN/A
Cap/Depr(3y)132.78%
Cap/Depr(5y)92.67%
Cap/Sales(3y)1.38%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.42%
EPS Next Y-60.6%
EPS Next 2Y-27%
EPS Next 3Y-10.55%
EPS Next 5Y29.44%
Revenue 1Y (TTM)54.52%
Revenue growth 3Y-12.33%
Revenue growth 5Y178.96%
Sales Q2Q%5556%
Revenue Next Year-63.67%
Revenue Next 2Y-10.08%
Revenue Next 3Y11.92%
Revenue Next 5Y43.11%
EBIT growth 1Y35.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.64%
OCF growth 3YN/A
OCF growth 5YN/A